2025
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
Johnson J, Siblini H, Al‐Hendy A, Segars J, González F, Taylor H, Singh B, Carson S, Christman G, Huang H, Dangi B, Zhang H. Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene. Clinical And Translational Science 2025, 18: e70189. PMID: 40077973, PMCID: PMC11903501, DOI: 10.1111/cts.70189.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCatechinClomipheneDrug Therapy, CombinationFemaleFolic AcidGenotypeHumansLeiomyomaLetrozoleMethylenetetrahydrofolate Reductase (NADPH2)TeaYoung AdultConceptsEpigallocatechin-3-gallateFolate levelsUterine fibroidsClinical trialsGreen tea extractAssociated with folate deficiencyPresence of MTHFRWomen of Childbearing AgeSerum folate levelsReduced folate levelsActive clinical trialsReproductive-age womenEffect of epigallocatechin gallateDHFR genotypeDHFR polymorphismTea extractDaily doseClomiphene citrateUnexplained infertilityFolate deficiencyChildbearing ageClinical studiesTreated womenFibroidsLetrozole
2018
Bazedoxifene–Conjugated Estrogens for Treating Endometriosis
Flores VA, Stachenfeld NS, Taylor HS. Bazedoxifene–Conjugated Estrogens for Treating Endometriosis. Obstetrics And Gynecology 2018, 132: 475-477. PMID: 29995747, DOI: 10.1097/aog.0000000000002739.Peer-Reviewed Original ResearchMeSH KeywordsAdultDrug Therapy, CombinationEndometriosisEstrogensEstrogens, Conjugated (USP)FemaleHumansIndolesSelective Estrogen Receptor ModulatorsConceptsConjugated estrogensPelvic painTreatment optionsStage III endometriosisCyclic pelvic painFirst-line therapyReproductive-aged womenPotential treatment optionManagement of dysmenorrheaUnfavorable side effectsEndometriotic lesionsGynecologic disordersHormonal agentsMenopausal symptomsOvarian parametersSide effectsAnimal studiesEndometriosisEstrogenBazedoxifenePainEffective alternativeFailure rateAbnormal effectsDysmenorrheaEffects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, Naftolin F, Harman SM, Miller VM. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause The Journal Of The North American Menopause Society 2018, 25: 145-153. PMID: 28832429, PMCID: PMC5771895, DOI: 10.1097/gme.0000000000000971.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyHormone therapyDomains of sleepSleep qualityDomain scoresMenopausal womenPrevention StudySleep domainsGlobal Pittsburgh Sleep Quality Index scoreOral conjugated equine estrogenPittsburgh Sleep Quality Index scorePittsburgh Sleep Quality IndexVasomotor symptom scoresConjugated equine estrogensSleep Quality IndexPoor sleep qualityGlobal sleep qualitySeverity of symptomsGlobal sleep scoreQuality Index scoresMenopausal hormonesVMS severityPostmenopausal womenVasomotor symptomsSpearman correlation coefficient
2017
Addition of Estradiol to Cross-Sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE−/− Mice
Goetz TG, Mamillapalli R, Sahin C, Majidi-Zolbin M, Ge G, Mani A, Taylor HS. Addition of Estradiol to Cross-Sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE−/− Mice. Endocrinology 2017, 159: 754-762. PMID: 29253190, PMCID: PMC5774248, DOI: 10.1210/en.2017-00884.Peer-Reviewed Original ResearchConceptsAtherosclerosis plaque formationLow-dose estradiolPlaque formationTestosterone therapyLesion progressionCross-sex hormone therapyEstradiol-treated miceLow-dose estrogenAtherosclerotic lesion progressionEffects of estrogenContribution of estradiolOil Red O stainAtherosclerosis lesion progressionAddition of estradiolWeeks of ageEstradiol therapyCardiovascular outcomesHormone therapyAortic sinusFemale ApoEAtherosclerosis progressionReduced atherosclerosisCombined therapyAortic archAtherosclerosis RiskLongitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo
Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo. Menopause The Journal Of The North American Menopause Society 2017, 24: 238-246. PMID: 27779568, PMCID: PMC5323337, DOI: 10.1097/gme.0000000000000756.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAutonomic Nervous System DiseasesDrug Therapy, CombinationEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleHot FlashesHumansIrritable MoodLongitudinal StudiesMiddle AgedPostmenopauseProgesteroneProgestinsSleep Initiation and Maintenance DisordersTreatment OutcomeVasomotor SystemConceptsOral conjugated estrogensActive treatment armsBody mass indexTreatment armsRace/ethnicityMonths postrandomizationNight sweatsPostmenopausal womenHot flashesMass indexMenopausal symptomsConjugated estrogensEarly postmenopausal womenMenopausal hormone therapyFinal menstrual periodProportion of womenHormone regimensTransdermal estradiolTransdermal estrogenHormone therapyVasomotor symptomsSymptom reliefTreat analysisActive treatmentConventional doses
2015
Predictors of participant retention in infertility treatment trials
Kuang H, Jin S, Thomas T, Engmann L, Hansen KR, Coutifaris C, Casson P, Christman G, Alvero R, Santoro N, Eisenberg E, Diamond MP, Legro RS, Zhang H, Network R, Bartlebaugh C, Dodson W, Estes S, Gnatuk C, Ladda R, Ober J, Easton C, Hernandez A, Leija M, Pierce D, Bryzski R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Lecks K, Martino L, Marunich R, Snyder P, Schlaff W, Comfort A, Crow M, Hohmann A, Mallette S, Ringbloom M, Tang J, Mason S, DiMaria N, Rhea M, Turner K, Haisenleder D, Trussell J, DelBasso D, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Zhang M, Lamar C, DePaolo L, Guzick D, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Predictors of participant retention in infertility treatment trials. Fertility And Sterility 2015, 104: 1236-1243.e2. PMID: 26354094, PMCID: PMC4630082, DOI: 10.1016/j.fertnstert.2015.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultChi-Square DistributionDrug Therapy, CombinationFemaleFertilityFertility Agents, FemaleHumansInfertility, FemaleLogistic ModelsMaleMultivariate AnalysisOdds RatioPatient DropoutsPatient SelectionPolycystic Ovary SyndromePregnancyRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeYoung AdultConceptsPolycystic ovary syndromeBody mass indexClomiphene citrateClinical trialsHistory of smokingInsurance coverageCombination of metforminMultivariable logistic modelAcademic medical centerRetention of subjectsConduct of RCTsBetter insurance coverageUnexplained infertilityOvary syndromeNormal weightMass indexOriginal RCTTreatment trialsMedical CenterMAIN OUTCOMEWhite raceIntervention studiesRCTsSecondary analysisParticipant retention
2012
Using bazedoxifene plus conjugated estrogens for treating postmenopausal women
Taylor HS, Ohleth K. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women. Menopause The Journal Of The North American Menopause Society 2012, 19: 479-485. PMID: 22278343, DOI: 10.1097/gme.0b013e31823dbbca.Peer-Reviewed Original ResearchConceptsBZA/CETissue selective estrogenConjugated estrogensPostmenopausal womenBone massSelective estrogenVulvar-vaginal atrophyPlacebo-controlled studyHot flush frequencyLevel I evidenceAmenorrhea ratesEndometrial hyperplasiaEndometrial stimulationHot flushesClinical outcomesClinical efficacyI evidenceFlush frequencySafety outcomesEstrogenPlaceboBazedoxifeneWomenOverall safetyUnexpected finding
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply